Cutter Capital Management LP Invests $6.23 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)

Cutter Capital Management LP acquired a new stake in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 112,500 shares of the company's stock, valued at approximately $6,229,000. Tarsus Pharmaceuticals makes up about 2.6% of Cutter Capital Management LP's holdings, making the stock its 19th biggest position. Cutter Capital Management LP owned 0.29% of Tarsus Pharmaceuticals at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Crowley Wealth Management Inc. acquired a new position in shares of Tarsus Pharmaceuticals in the fourth quarter valued at about $25,000. R Squared Ltd acquired a new position in shares of Tarsus Pharmaceuticals during the 4th quarter worth approximately $53,000. Quarry LP bought a new position in shares of Tarsus Pharmaceuticals during the fourth quarter worth approximately $166,000. HighTower Advisors LLC acquired a new stake in shares of Tarsus Pharmaceuticals in the fourth quarter valued at approximately $207,000. Finally, Summit Investment Advisors Inc. boosted its stake in shares of Tarsus Pharmaceuticals by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 3,848 shares of the company's stock valued at $213,000 after buying an additional 244 shares during the period. Institutional investors own 90.01% of the company's stock.

Tarsus Pharmaceuticals Stock Up 1.4 %

Shares of TARS opened at $48.00 on Tuesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. Tarsus Pharmaceuticals, Inc. has a 52 week low of $20.08 and a 52 week high of $57.28. The stock has a market capitalization of $2.02 billion, a price-to-earnings ratio of -12.60 and a beta of 0.94. The stock has a fifty day moving average of $48.05 and a 200-day moving average of $48.98.

Tarsus Pharmaceuticals (NASDAQ:TARS - Get Free Report) last posted its earnings results on Thursday, May 1st. The company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.05. The firm had revenue of $78.34 million during the quarter, compared to the consensus estimate of $72.50 million. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. As a group, sell-side analysts anticipate that Tarsus Pharmaceuticals, Inc. will post -3.17 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Tarsus Pharmaceuticals news, General Counsel Bryan Wahl sold 3,341 shares of the company's stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $46.29, for a total value of $154,654.89. Following the sale, the general counsel now owns 58,057 shares in the company, valued at approximately $2,687,458.53. The trade was a 5.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Bobak R. Azamian sold 6,000 shares of the firm's stock in a transaction dated Monday, March 24th. The stock was sold at an average price of $50.00, for a total value of $300,000.00. Following the transaction, the chief executive officer now owns 824,106 shares of the company's stock, valued at $41,205,300. This trade represents a 0.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 32,542 shares of company stock worth $1,581,173 in the last ninety days. Company insiders own 8.25% of the company's stock.

Analysts Set New Price Targets

A number of research firms have recently weighed in on TARS. HC Wainwright reiterated a "buy" rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. Guggenheim boosted their target price on shares of Tarsus Pharmaceuticals from $78.00 to $84.00 and gave the company a "buy" rating in a research report on Friday. Barclays lowered their price objective on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an "overweight" rating for the company in a research report on Wednesday, February 26th. The Goldman Sachs Group raised their target price on Tarsus Pharmaceuticals from $46.00 to $51.00 and gave the company a "neutral" rating in a report on Monday. Finally, Jefferies Financial Group boosted their price target on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a "buy" rating in a report on Thursday, March 6th. One research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $66.33.

Tarsus Pharmaceuticals Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.

Want to see what other hedge funds are holding TARS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.